Theragnostic Approach of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) – The Role of Nuclear Medicine (NM) in a Multidisciplinary Team Abstract #1469

Introduction: NET pts are a clinical challenge requiring intervention of multiple medical specialties
Aim(s): Our work focuses on diagnostic and therapeutic role of NM in multidisciplinary team using functional features of NETs
Materials and methods: GEP-NET cases were examined focusing on those who did NM diagnostic (somatostatin receptor scintigraphy-SRS/positron emission tomography-PET for evaluation of receptor status/disease extent, evaluation of response to therapy; 18F-FDG PET for evaluation of undifferentiated component) and therapeutic (177Lu-DOTATATE peptide radionuclide radiotherapy-PRRT) procedures
Conference: 13th Annual ENETS conference 2016 (2016)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Dr Teresa Lucio
Keywords: PRRT, GEP-NET

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2849 PRRT Neuroendocrine Tumor Response Assessment Using Circulating Transcript Analysis: The NETest
Introduction: The absence of an accurate blood biomarker to predict and monitor PRRT is a key unmet need.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: MD, PhD Lisa Bodei
#2866 Extrahepatic 68Ga-DOTATATE-Avid Tumor Volume and Serum Chromogranin A Predict Short-Term Outcome of 177Lu-DOTATATE in Late-Stage Metastatic Gastroenteropancreatic Neuroendocrine Tumors
Introduction: 177Lu-DOTATATE is an effective therapy for somatostatin receptor-positive neuroendocrine tumors (NETs). Often enough 177Lu-DOTATATE is used as the last treatment resort in advanced NET.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Hong Hong Song
Authors: Song H, Kunz P, Franc B, Moradi F, ...
#1530 Bizarre Neuroendocrine Tumour Presentations
Introduction: Herein we present two cases of neuroendocrine tumours (NET)with atypical presentations.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Clinical cases/reports
Presenting Author: Carolina Palmela
#2698 Safety and Efficacy of Salvage PRRT with 177Lu-DOTA-Octreotate in Patients with Well-Differentiated Metastatic Neuroendocrine Tumours (NET)
Introduction: Peptide receptor radionuclide therapy (PRRT) is an effective therapy in patients with a somatostatin receptor-positive neuroendocrine tumour (NET). NETTER-1 trial demonstrated high efficacy and low toxicity of four cycles.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Nariman Ghaleb
#2770 Evaluation of Early Predictors of Metabolic Syndrome in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET)
Introduction: Metabolic syndrome and obesity (MetS) are supposed to have a role in cancer but data analysing their association with GEP-NET are lacking.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MD, PhD Roberta Modica